Analysts Expect Crispr Therapeutics AG (NASDAQ:CRSP) Will Announce Earnings of -$1.09 Per Share

Wall Street brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings per share (EPS) of ($1.09) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Crispr Therapeutics’ earnings, with estimates ranging from ($1.17) to ($0.96). Crispr Therapeutics posted earnings per share of ($0.93) during the same quarter last year, which would suggest a negative year-over-year growth rate of 17.2%. The company is scheduled to issue its next earnings results on Monday, May 4th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($4.54) per share for the current year, with EPS estimates ranging from ($5.22) to ($3.70). For the next year, analysts expect that the company will post earnings of ($5.05) per share, with EPS estimates ranging from ($7.14) to ($3.78). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of ($0.68) by $1.19. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm had revenue of $77.00 million for the quarter, compared to analysts’ expectations of $39.08 million. During the same period in the previous year, the business earned ($0.92) earnings per share. Crispr Therapeutics’s revenue for the quarter was up 76900.0% compared to the same quarter last year.

A number of equities analysts recently weighed in on CRSP shares. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. William Blair reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Piper Sandler reissued a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research note on Thursday, February 13th. BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 19th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $72.25.

Large investors have recently added to or reduced their stakes in the business. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in Crispr Therapeutics during the 4th quarter valued at about $26,000. Webster Bank N. A. purchased a new position in Crispr Therapeutics during the 4th quarter valued at about $26,000. Advisory Services Network LLC grew its stake in Crispr Therapeutics by 146.0% during the 4th quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock valued at $41,000 after acquiring an additional 400 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in Crispr Therapeutics during the 4th quarter valued at about $44,000. Finally, Exchange Traded Concepts LLC purchased a new position in Crispr Therapeutics during the 4th quarter valued at about $54,000. 52.02% of the stock is currently owned by institutional investors.

Shares of Crispr Therapeutics stock opened at $42.66 on Wednesday. The company’s 50-day moving average price is $49.19 and its two-hundred day moving average price is $52.94. Crispr Therapeutics has a 52 week low of $32.30 and a 52 week high of $74.00. The stock has a market cap of $2.41 billion, a PE ratio of 43.98 and a beta of 2.74.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is Green Investing?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.